The clinical efficacy, patient tolerance, and pharmacokinetics-of gentamicin and the single component gentamicin C1 were studied after single and multiple doses in elderly male patients. Patient tolerance was extremely good at the dose levels used. There was some evidence of renal function impairment due to repeated intramuscular doses of gentamicin, but not gentamicin C1. The antibiotics were equally effective against the organisms present in the urine of these patients. The pharmacokinetics of the two antibiotic forms were similar, although gentamicin C appeared to have a larger distribution space.
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Gentamicin, a broad-spectrum antibiotic complex, has been shown to consist of three components designated C l, C la, and C2 (2) . The recent availability of each component in substantially pure form has permitted their comparative evaluation with the parent complex in a variety of in vitro and in vivo studies. It was noted that gentamicin C1 (SCH 13706) required a significantly longer period of administration to produce ataxia in cats than did the gentamicin complex. Similar observations, together with reduced nephrotoxicity due to gentamicin C1, were made in the squirrel monkey. Studies in other species also demonstrated reduced eighth cranial nerve and renal toxicity with gentamicin C1 (2) .
In vitro bacteriological studies and in vivo mouse protection studies indicate that gentamicin C1 is slightly less active than the gentamicin complex against most strains of Enterobacteriaceae. Cross-resistance between gentamicin Cl and the parent complex is generally noted, although the former is not inactivated by bacterial acetylases (2) .
Since it thus appears that gentamicin C 1 may offer therapeutic advantages over gentamicin, the two antibiotics were compared in the clinical treatment of complicated urinary tract infections, with particular emphasis on efficacy, tolerance, and pharmacokinetics. Therapeutic results were defined according to the urine cultures: cure, negative culture at 1 week after treatment; persistence, >100,000 colonies/ml of the original bacteria during treatment; relapse, negative culture during therapy and >100,000 colonies/ml of the original organism at follow-up; reinfection, > 100,000 colonies/ml different from the original bacteria at the follow-up; and superinfection, >100,000 colonies/ml different from the original bacteria during therapy. Microorganisms were identified by routine bacteriological methods without specific typing.
MATERIALS AND MErHODS

RESULTS
Clinical efficacy. The bacteriological results from the two treatments are given in Table 1 . Similar results were obtained with both treatments. Although a slightly higher cure rate was obtained with gentamicin, the differences observed between the treatment were not clinically significant.
Tolerance. The intramuscular injections of the two antibiotics caused only minimal discomfort. There were no changes in values for serum alkaline phosphatase, glutamic oxaloacetic transaminase, serum bilirubin, hemoglobin, or leukocyte count with differential before or after treatment with either compound, and no changes in audiograms were observed. Table 2 illustrates renal function as expressed by blood urea nitrogen, serum creatinine, and creatinine clearance before and after treatments. No changes were observed except for an increase in serum creatinine after gentamicin dosing, which was of borderline significance.
Serum and urine antibiotic levels. Mean serum and urine antibiotic concentrations after both treatments, together with cumulative urinary excretion, are given in Table 3 , and mean serum levels are illustrated in FIG. 1 . Serum concentrations of gentamicin were generally higher than those for gentamicin C1, and higher concentrations of both antibiotics were obtained after multiple dosing due to accumulation. Both treatments resulted in similar urinary concentrations and cumulative urinary excretion of antibiotic after the first and last doses. The data for gentamicin are similar to those Obtained by other investigators ever, the serum concentrations wei those reported previously, and ti been due to resistance to drug extravascular spaces in these ol The distribution volume of gentan first intravenous dose was 17 ±: -error) of body weight, whereas the cin C1 was 25 ± 1.5% of body w appears that this single compone: into extravascular spaces more ree (9) , no adverse effects were associated with the present gentamicin C, treatment. Due to the similarity in the clinical efficacy of the two treatments and the absence of any toxic symptoms with gentamicin C,, it appears that this single component may offer some slight advantage over gentamicin.
The present results were obtained in a special patient population, and therefore further studies will be needed to compare the relative efficacy and tolerance of the two antibiotics in a 
